title: Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases.
abstract: OBJECTIVE
  We report a prospective randomized study comparing survival, response and toxicity in colorectal liver metastasis (CLM) patients treated by either hepatic arterial floxuridine (HAI) plus continuous systemic fluorouracil/folinic acid or systemic fluorouracil/folinic acid.
  
  
  METHODS
  Eighty-four CLM patients received either HAI plus systemic fluorouracil/folinic acid or systemic fluorouracil/ folinic acid.
  
  
  RESULTS
  Significantly more HAI plus systemic, compared with systemic only, patients developed WHO grade 3 or 4 diarrhoea (P=0.004), but significant quality of life differences were not detected. Liver metastasis partial response at 4 months after randomization was significantly greater (P=0.003) in HAI plus systemic (13/29, 45%) compared with systemic only (7/30, 23%) patients. There was no significant difference between groups in the proportion of patients who died from extrahepatic disease progression, or in survival.
  
  
  CONCLUSIONS
  Combining regional with systemic fluorinated pyrimidines did not improve survival compared with systemic fluorinated pyrimidine.
authors.affiliation: Department of Surgical Oncology, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK. t.allenmersh@ic.ac.uk
authors.forename: T G
authors.initials: TG
authors.lastname: Allen-Mersh
authors.forename: C
authors.initials: C
authors.lastname: Glover
authors.forename: C
authors.initials: C
authors.lastname: Fordy
authors.forename: P
authors.initials: P
authors.lastname: Mathur
authors.forename: H
authors.initials: H
authors.lastname: Quinn
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D014408:Biomarkers, Tumor / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D015179:Colorectal Neoplasms / Q000276:immunology / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage* / Q000009:adverse effects; D006397:Hematinics / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000009:adverse effects / Q000295:instrumentation; D007262:Infusions, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D006397:Hematinics; D005467:Floxuridine; D002955:Leucovorin